CenterBook Partners LP Sells 2,693 Shares of Medpace Holdings, Inc. $MEDP

CenterBook Partners LP trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 42.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,603 shares of the company’s stock after selling 2,693 shares during the period. CenterBook Partners LP’s holdings in Medpace were worth $2,024,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MEDP. Palladiem LLC bought a new position in shares of Medpace in the 4th quarter worth about $100,000. Los Angeles Capital Management LLC boosted its position in shares of Medpace by 11.7% in the 4th quarter. Los Angeles Capital Management LLC now owns 89,741 shares of the company’s stock worth $52,083,000 after purchasing an additional 9,380 shares in the last quarter. Cookson Peirce & Co. Inc. grew its stake in shares of Medpace by 508.0% in the 4th quarter. Cookson Peirce & Co. Inc. now owns 2,900 shares of the company’s stock worth $1,629,000 after buying an additional 2,423 shares during the last quarter. Havemeyer Place LP purchased a new stake in shares of Medpace in the 4th quarter worth approximately $1,172,000. Finally, Vestcor Inc increased its position in Medpace by 66.3% during the 4th quarter. Vestcor Inc now owns 4,442 shares of the company’s stock valued at $2,495,000 after buying an additional 1,771 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP stock opened at $466.79 on Wednesday. The company’s fifty day moving average price is $456.86 and its 200-day moving average price is $506.57. Medpace Holdings, Inc. has a one year low of $294.07 and a one year high of $628.92. The company has a market capitalization of $13.33 billion, a PE ratio of 29.34, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the firm posted $3.67 EPS. Medpace’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The SEC filing for this sale provides additional information. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Robert W. Baird dropped their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and dropped their price target for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Barclays reduced their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.